Skip to Main Content

Paper Details

t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity.
Blood Adv
3
2022
-PDGFRA fusion, -PDGFRA fusions, -SCFD2 fusion, 4q12, 4q12 partners, AML, Acute myeloid leukemia, CHIC2, ETV6, ETV6-PDGFRA fusion, GSX2, PDGFRA, PDGFRA 4q12 genes, PDGFRA-containing fusions, RNA, SCFD2, clinically, eosinophilia, eosinophilic disorders, genes, genomic regions, hematopoietic malignancies, imatinib, non-, patient, patients, t, t(4;12)(q12;p13, t(4;12)(q12;p13), t(4;12)(q12;p13) translocation
Author NameAffiliation
Dora Dias-SantagataMassachusetts General Hospital
Jochen K LennerzMassachusetts General Hospital
Anthony J IafrateMassachusetts General Hospital
Marlise R LuskinDana-Farber Cancer Institute
Daniel J DeAngeloDana-Farber Cancer Institute
Richard M StoneDana-Farber Cancer Institute
  • 1 - 6

Datasets

Release 1.2